Navigation Links
CardioMEMS Recognized by Georgia Bio for Pivotal Strategic Partnership
Date:1/21/2011

ATLANTA, Jan. 21, 2011 /PRNewswire/ -- CardioMEMS, Inc., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, has earned a Georgia Bio (GaBio) 2011 Deal of the Year award.  CardioMEMs was recognized in the Strategic Partnership category for the $60 million equity investment it secured from St. Jude Medical (NYSE: STJ). The investment, which was made in September 2010, followed the successful completion in 2010 of CardioMEMS' CHAMPION clinical study of its wireless, implantable pressure monitor for heart failure.

Georgia Bio announced its 2011 Deal of the Year awards for medical device and biopharmaceutical companies at the GaBio Annual Awards Dinner held at Atlanta's Fox Theater on January 20. The annual awards recognize transactions by life sciences companies in Georgia that are significant to the state's industry development. To reflect a broad range of activity in the midst of a challenging economic environment, the awards are given in four categories:  public and private financings, strategic partnerships and product launches.

"We are proud to be recognized by Georgia Bio," said Jay Yadav, M.D., founder and CEO of CardioMEMS and an interventional cardiologist. "We have achieved our immediate goals with the successful conclusion of the CHAMPION trial.  As we work toward the commercialization of this promising technology, we are excited to partner with St. Jude Medical and its significant expertise and focus in heart failure disease and cardiac rhythm management."

The Champion™ wireless HF sensor is an innovative miniature device that is implanted into the patient's pulmonary artery using a simple, catheter-based procedure. The pulmonary artery pressure is then measured and displayed using the CardioMEMS proprietary electronic monitoring system. Following the procedure, patients perform wireless measurements of their pulmonary artery pressure from home. The pressure data is immediately transmitted to a secure database and is available for review by the implanting physician on the CardioMEMS proprietary website.

St. Jude Medical's $60 million investment provided the global medical device company a 19% ownership in CardioMEMS and an exclusive option to acquire the remaining 81% of CardioMEMS for an additional $375 million during a period that extends through the completion of certain commercialization milestones. In May 2010, CardioMEMS raised approximately $38 million in a financial investor round lead by John Huntz and the Atlanta office of Arcapita, a global investment company.  With the strategic investment by St. Jude Medical, CardioMEMS has raised over $98 million in 2010.

In addition to a Georgia Bio 2011 Deal of the Year award, the Southeastern Medical Device Association (SEMDA) awarded Dr. Yadav its 2010 SpotLight Award for outstanding achievement in fostering the growth of the medical device community in the Southeast, and TiE Atlanta recognized CardioMEMS with its 2010 Entrepreneurial Award for the Deal of the Year for securing the St. Jude Medical investment. Dr. Yadav also delivered the keynote speech recently for Southeast BIO's (SEBIO) 12th Annual Investor Forum where he shared his views on the challenges of building innovative medical device start-up companies to over 350 biotech and medical technology executives, entrepreneurs, venture capitalists and investment bankers from the Southeast.

About Georgia Bio

Georgia Bio is the private, non-profit association representing nearly 300 pharmaceutical, biotech and medical device companies, universities, research institutes, government groups and other organizations involved in the development of products that improve the health and well-being of people, animals and the environment. More information is located at www.gabio.org.

About CardioMEMS, Inc.

CardioMEMS is a medical device company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body. The Company's technology platform is designed to improve the management of severe chronic cardiovascular diseases such as aneurysms, heart failure and hypertension. CardioMEMs miniature wireless sensors can be implanted using minimally-invasive techniques and transmit cardiac output, blood pressure and heart rate data which are critical to the management of patients. The sensors are designed to be permanently implanted into the heart and blood vessels due to their small size, durability and lack of wires and batteries. Using radiofrequency (RF) energy, the sensors transmit real-time data to external electronic readers, which then communicate this information to the patient's physician. The Company developed this technology based on the belief that frequent, on-demand, real-time monitoring of vital information enables proactive patient management, which holds the promise of reducing hospitalizations, improving a patient's quality of life and delivering more efficient and cost effective health care. More information about the CardioMEMs is located at www.cardiomems.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS and the CardioMEMS logo are registered trademarks of CardioMEMS, Inc.

Champion is a trademark of CardioMEMS, Inc.


'/>"/>
SOURCE CardioMEMS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
2. CardioMEMS Completes CHAMPION Clinical Trial Study
3. Boston Millennia Partners Portfolio Company CardioMEMS Signs Equity Investment and Exclusive Option to be Acquired for an Additional $375,000,000
4. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
5. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
6. invivodata Recognized as One of Pittsburghs Fastest Growing Private Companies
7. Roche Scientist Recognized for Excellence in Peptide Chemistry
8. SEI Defined Benefit Client Recognized With Leading Plan Design Award
9. Nonin Medical Recognized for Influential Contributions in Medical Technology
10. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
11. AQUA(R) Technology Recognized as Promising New Strategy for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... 2017 , ... Demand generation pioneer True Influence has announced ... The Marketing Tech Conference October 2–4, at the Hynes Convention Center in Boston, ... representing such thought-leading companies as JP Morgan Chase, GE Digital, and Dun & ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) ... HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, 2017 to assist ... offering these discounted prices to all businesses and government agencies – whether or not ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm ... Friday, September 8, and Monday, September 11, off work and rolled up their sleeves ... before heading to local homes to start the process of rebuilding. , CORDA founder ...
Breaking Medicine News(10 mins):